ClinicalTrials.gg
RecruitingNCT07401732Updated Oct 5, 2026

Dysphagia in Rheumatoid Arthritis

An observational study in Rheumatoid Arthritis (RA, sponsored by Tanta University. Recruiting at 2 sites in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Tanta University · Observational

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Oct 5, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
30
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Arthritis, Rheumatoid by Tanta University — 11 open to participants now, 11 under way, 3 of them phase 3. Arthritis, Rheumatoid · Tanta University.

Started
2026
with 4 others
Observational
Only one
of the 15
Primary completion
2026-11
later than 6 of 10 live
Registered
12th of 15
by date

Among the 15 studies in Arthritis, Rheumatoid by Tanta University, this one is one of 5 that started in 2026, is the only observational one, reaches primary completion later than 6 of the 10 other live ones, and was the 12th registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

11 of the 15 studies in Arthritis, Rheumatoid by Tanta University are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Arthritis, Rheumatoid by Tanta University, or all of them as a file.
02

Study summary

The primary goal of this cross-sectional study is to assess risk factors/predictors for dysphagia in RA.

The secondary goals include demonstrating whether flexible fiberoptic pharyngolaryngoscopy can detect joint-affection-induced dysphagia in patients with rheumatoid arthritis (RA) and whether both oropharyngeal and esophageal dysphagia are present among these patients.

The main questions it aims to answer are

  • What are the predictors that are associated with dysphagia via flexible fiberoptic pharyngolaryngoscopy in rheumatoid arthritis patients?
  • Whether flexible fiberoptic pharyngolaryngoscopy can detect joint-affection-induced dysphagia in patients with RA?
  • Whether both oropharyngeal and esophageal dysphagia are present in patients with RA?
Read the detailed description

This cross-sectional study will comprise RA patients during their visits to inpatient and outpatient clinics. The inclusion criterion is patients with RA defined by the American College of Rheumatology/European League Against Rheumatism collaborative initiative (ACR/EULAR) 2010 classification criteria. Patients aged above 18 years old, well-orientated, and cooperative.

03

Conditions studied

  • Rheumatoid Arthritis (RA

Keywords

  • Flexible Endoscopic Evaluations of Swallowing
  • Temporomandibular joint
  • Deglutition disorders
  • cricoarytenoid
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with RA defined by the American College of Rheumatology/European League Against Rheumatism collaborative initiative (ACR/EULAR) 2010 classification criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with Rheumatoid arthritis defined by the American College of Rheumatology/European League Against Rheumatism collaborative initiative (ACR/EULAR) 2010 classification criteria.
  • Patients aged above 18 years old, well-orientated, and cooperative.

Exclusion criteria

Exclusion Criteria:

  • concomitant thyroid dysfunction.
  • concomitant hypovitaminosis D.
  • concomitant cancer diagnosis, pregnancy.
  • jaw-related traumas, teeth, and gum diseases.
  • other rheumatologic conditions
  • other comorbidities.
  • other causes of TMJ arthritis, patients with TMJ, palatal or tongue congenital abnormalities, and patients who underwent TMJ injections in the last six months.
  • Patients with any language disorders or intellectually handicapped (as certain questions depend on the patient's ability to comprehend and express their emotions regarding their issue) and patients with anatomical anomalies impeding the functionality of flexible nasofibroscopy.
  • Any apparent causes of dysphagia other than RA.
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • Interventional Study Model

    Single Group Assignment (rheumatoid arthritis patients)

    Diagnostic Test: flexible fiberoptic pharyngolaryngoscopy

Interventions

  • Diagnostic testflexible fiberoptic pharyngolaryngoscopy

    Flexible Endoscopic Evaluations of Swallowing (FEES) will be used to examine the nose, throat, and airway to diagnose possible causes of dysphagia. The dysphagia severity scale via FEES will be scored. It is a flexible process that may be applied to a variety of situations and objectives (named as flexible pharyngolaryngoscopy). Following the routine oropharyngeal examination, its versatility can enable it to be used as a laryngoscope for examining the larynx and adjacent regions.

06

What researchers measure

Primary outcomes

  1. Identifying potential predictors of dysphagia severity in rheumatoid arthritis patients.

    Demonstrating the associations between the dysphagia severity scale (DSS) via flexible/fibre-optic endoscopic evaluations of swallowing (FEES) and the following: 1. Active disease by disease activity score in 28 joints with C-reactive protein (DAS28-CRP ): low if DAS28-CRP score was less than 3.2, moderate if the score between 3.2 and 5.1, or high if the score \> 5.1. 2. RA patient's malfunction by Modified Health Assessment Questionnaire (MHAQ): mild functional loss if score less than 1.3, moderate if score between 1.3 and 1.8, severe loss if \> 1.8 3. Temporomandibular dysfunction: mild TMJ dysfunction if score from 20 to 40, moderate dysfunction if score from 45 to 65 and severe TMJ dysfunction if the score from 70 to 100. 4. Cricoarytenoid joint dysfunction. 5. Specific change in temporomandibular (TMJ) joints by cone beam CT imaging.

    Time frame: The assessment of dysphagia severity via FEES typically will take nearly 25 minutes. The duration of clinical, laboratory, and radiological tests will take 1 to 2 days and may vary depending on the specific circumstances.

Secondary outcomes

  1. Demonstrating whether flexible fiberoptic pharyngolaryngoscopy can diagnose Joint-Affection-Induced dysphagia in patients with RA.

    Flexible Endoscopic Evaluations of Swallowing (FEES) will be used to examine the nose, throat, and airway to diagnose possible causes of dysphagia. It is a flexible process that may be applied to a variety of situations and objectives (named as flexible pharyngolaryngoscopy). Following the routine oropharyngeal examination, its versatility can enable it to be used as a laryngoscope for examining the larynx and adjacent regions.

    Time frame: Assessment of rheumatoid arthritis patients by FEES will take 10 to 25 minutes. The duration may vary depending on the specific circumstances and the complexity of the assessment.

  2. Demonstrating whether both oropharyngeal and oesophageal dysphagia are present among patients with RA?

    An upper oesophagus examination by FEES may provide a useful screening tool for oesophageal dysphagia in addition to the routine oropharyngeal and laryngeal examination.

    Time frame: up to 2 minutes following routine FEES.

07

Study locations

2 of 2 sites recruiting
  • Faculty of medicine, Tanta University
    Tanta, Elgharbia 31151, Egypt
    Recruiting
    • Ayman Fouad, MD · Sub investigator
    • Basma ES Elmorshidy, MD · Sub investigator
    • MennatAllah EA Gahgah, MD · Sub investigator
    • Elsayed Rageh, MD · Sub investigator
    • Heba Hanout · Sub investigator
    • Abdallah Allam · Sub investigator
    • Rehab Ghoraba, MD · Sub investigator
    • Aliaa MA Farag, MD · Principal investigator
  • Rheumatology, rehabilitation, and physical medicine department Faculty of medicine, Tanta University
    Tanta, Elgharbia 31151, Egypt
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Data is available with corresponding author on reasonable request.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Feb 2026 (actual). Primary completion is estimated for Nov 2026, 9 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: primary completion Aug 2026 → Nov 2026 and completion Aug 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2026
First posted
Feb 10, 2026
StartActual
Feb 7, 2026
Primary completionEst.
Nov 2026was Aug 2026
CompletionEst.
Nov 2026was Aug 2026
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 2026→Nov 2026
Oct 5, 2026
Study completion
Aug 2026→Nov 2026
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Primary completion Aug 2026→Nov 2026
    Study completion Aug 2026→Nov 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07401732
Lead sponsor
Tanta University
Responsible party
Aliaa Mamdouh Abdelaziz Farag (Lecturer, Tanta University) — Principal investigator
First posted
Feb 10, 2026
Start date
Feb 7, 2026
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Oct 5, 2026

Study contacts

Aliaa MA Farag, MD
Contact
aliaa.mamdouh@med.tanta.edu.eg
+201069468486
Ayman Fouad, MD
Contact
aymanfouadtanta@med.tanta.edu.eg
+20 10 04398763
Aliaa MA Farag, MD
principal investigator · Tanta University Faculty of Medicine

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion